Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Harmony Gold Mining Co. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.89 (market cap $8.04B), while Harmony Gold Mining Co. trades at $15.09 (market cap $9.59B). The key difference: Harmony Gold Mining Co. is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 2.67% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | HMY | |
|---|---|---|
Market Cap | $8.04B | $9.59B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $26.04 |
52-Week Low | $241.71 | $12.61 |
Enterprise Value | $7.85B | $9.93B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Harmony Gold Mining (HMY) trades at $14.99, down 0.79% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with 2024 revenue of $61.38 billion and net income of $8.59 billion, yielding robust profitability margins. Recent earnings were mixed, beating in Q2 2025 but missing in Q4 2025. Analyst sentiment is cautious with 70% hold ratings, while news highlights stock volatility tied to gold price sensitivity and Fed policy expectations.
HMY presents a valuation opportunity with low P/E (9.59) and EV/EBITDA (5.05) multiples, supported by high ROE (32.32%) and a 4.06% dividend yield. Key risks include gold price exposure, operational execution in its pivot to gold-copper hybrid model, and macroeconomic headwinds from potential interest rate hikes. Institutional consensus leans neutral, suggesting patience for copper project contributions to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
